Esperion Therapeutics Shares Rise After Narrower-Than-Expected Loss, Revenue Beat in Q2

MT Newswires Live

Aug 06

Esperion Therapeutics (ESPR) shares were up 10% in recent trading on Tuesday after the drugmaker reported a narrower-than-expected loss and revenue beat in Q2.

The company earlier reported a Q2 net loss of $0.02 per diluted share, narrowing from a loss of $0.33 a year earlier.

Analysts polled by FactSet expected a loss of $0.15.

Revenue for the quarter ended June 30 rose to $82.4 million from $73.8 million a year earlier.

Analysts surveyed by FactSet expected $63 million.

Price: 1.64, Change: +0.15, Percent Change: +10.07

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557411316"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557411316\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557411316?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 02:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557411316","market":"sh","top_or_hot":-1,"title":"Esperion Therapeutics Shares Rise After Narrower-Than-Expected Loss, Revenue Beat in Q2","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ESPR\">Esperion Therapeutics</a> (ESPR) shares were up 10% in recent trading on Tuesday after the drugmaker reported a narrower-than-expected loss and revenue beat in Q2.</p><p>The company earlier reported a Q2 net loss of $0.02 per diluted share, narrowing from a loss of $0.33 a year earlier.</p><p>Analysts polled by FactSet expected a loss of $0.15.</p><p>Revenue for the quarter ended June 30 rose to $82.4 million from $73.8 million a year earlier.</p><p>Analysts surveyed by FactSet expected $63 million.</p><p>Price: 1.64, Change: +0.15, Percent Change: +10.07</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Esperion Therapeutics Shares Rise After Narrower-Than-Expected Loss, Revenue Beat in Q2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEsperion Therapeutics Shares Rise After Narrower-Than-Expected Loss, Revenue Beat in Q2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-06 02:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ESPR\">Esperion Therapeutics</a> (ESPR) shares were up 10% in recent trading on Tuesday after the drugmaker reported a narrower-than-expected loss and revenue beat in Q2.</p><p>The company earlier reported a Q2 net loss of $0.02 per diluted share, narrowing from a loss of $0.33 a year earlier.</p><p>Analysts polled by FactSet expected a loss of $0.15.</p><p>Revenue for the quarter ended June 30 rose to $82.4 million from $73.8 million a year earlier.</p><p>Analysts surveyed by FactSet expected $63 million.</p><p>Price: 1.64, Change: +0.15, Percent Change: +10.07</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESPR","symbol_name":"Esperion Therapeutics Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2557411316","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557411316","pubTimestamp":1754419115,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Esperion Therapeutics  shares were up 10% in recent trading on Tuesday after the drugmaker reported a narrower-than-expected loss and revenue beat in Q2.The company earlier reported a Q2 net loss of $0.02 per diluted share, narrowing from a loss of $0.33 a year earlier.Analysts polled by FactSet expected a loss of $0.15.Revenue for the quarter ended June 30 rose to $82.4 million from $73.8 million a year earlier.Analysts surveyed by FactSet expected $63 million.Price: 1.64, Change: +0.15, Percent Change: +10.07","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ESPR":"Esperion Therapeutics Inc."},"translate_title":"Esperion Therapeutics第二季度亏损收窄、营收好于预期后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":1},"content_text":"Esperion Therapeutics (ESPR) shares were up 10% in recent trading on Tuesday after the drugmaker reported a narrower-than-expected loss and revenue beat in Q2.The company earlier reported a Q2 net loss of $0.02 per diluted share, narrowing from a loss of $0.33 a year earlier.Analysts polled by FactSet expected a loss of $0.15.Revenue for the quarter ended June 30 rose to $82.4 million from $73.8 million a year earlier.Analysts surveyed by FactSet expected $63 million.Price: 1.64, Change: +0.15, Percent Change: +10.07","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}